Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PBYI $224.58 165.5500 +280.45%
INO $13.34 2.2000 +19.75%
ARRY $4.30 0.3700 +9.41%
DYAX $9.19 0.3900 +4.43%
EPZM $31.48 1.0700 +3.52%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

GSK $50.42 -2.8035 -5.27%
AEZS $1.16 -0.0400 -3.33%
SRNE $5.34 -0.1000 -1.84%
AVEO $1.17 -0.0200 -1.68%
FATE $6.40 -0.0700 -1.08%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

FDA Committee to Discuss Adverse Effects of Testosterone Products

(Reuters) July 17, 2014 - The U.S. Food and Drug Administration has called an advisory committee meeting on Sept. 17, to discuss the adverse cardiovascular outcomes with the usage of testosterone replacement therapy.
read article 

AbbVie Clinches $54 Billion Deal For Shire in Huge Inversion to Cut Taxes

(New York Times/DealBook) July 18, 2014 - The pharmaceutical giant AbbVie agreed on Friday to buy its European rival Shire for around $54 billion in the biggest takeover deal so far this year.
read article 

Mark Soloway, MD, Internationally Recognized Leader in Urologic Oncology, Joins Memorial Cancer Institute to Start New Division

(PRWeb) July 17, 2014 - Dr. Mark Soloway, who has been appointed Chief of Urologic Oncology at Memorial Cancer Institute, will lead a new division focused on the care of bladder, prostate and kidney cancers, while also establishing a research program.
read press release 

Huntsman Cancer Institute Receives Funding to Establish a National Clinical Trials Network Site

(HCI/U of U) July 17, 2014 - A team of physician-researchers from Huntsman Cancer Institute (HCI) at the University of Utah (U of U) will receive nearly $3.6 million over the next five years in a cooperative agreement with the National Institutes of Health (NIH) to establish a Network Lead Academic Participating Site (NLAPS).
read press release 

In Defense of Prostate Cancer Screening

(Forbes) July 17, 2014 - Have you ever asked your plastic surgeon advice on prostate cancer screening? Or the utility of an annual physical exam?
read article 

New European Clinical Practice Guidelines For Anal Cancer

(Medscape Medical News) July 17, 2014 - Three European societies have jointly issued clinical practice guidelines for the diagnosis, treatment, and follow-up of anal cancer. The guidelines were published online July 6 in the Annals of Oncology.
read article (free registration required) 

Obamacare Had 'Nothing to Do With' the Cancer Centers of N.C. Closing

(Triangle Business Journal) July 16, 2014 - When the Cancer Centers of North Carolina close their doors for good on Oct. 1, the Affordable Care Act will have played no role.
read article 

Local Cancer Center Drops Obamacare Patients

(Las Vegas Review-Journal) July 17, 2014 - A billing dispute has cost enrollees in the state’s health insurance exchange access to Southern Nevada’s largest oncology practice.
read article 

Thumbs Up, Down for Study on New Cancer Pay Scheme

(Medscape Medical News) July 17, 2014 - A mixture of skepticism and applause has been the reaction to a study of a payment model for cancer care that yielded huge savings over the conventional fee-for-service model.
read article (free registration required) 

Rexahn Pharmaceuticals Provides Update on Phase I Supinoxin Trial in Cancer Patients with Solid Tumors

(MarketWatch) July 18, 2014 - Rexahn Pharmaceuticals, Inc. today announced an update in its Phase I multi-center dose-escalation study to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin™ (RX-5902) in cancer patients with solid tumors.
read article 

One Third of Cancer Patients Are Killed by a ‘Fat-Burning’ Process Termed Cachexia Related to Obesity, CNIO Researchers Say

(CNIO [Madrid, Spain]) July 17, 2014 - Most cancer researchers are working on the biology of the tumour. However, Michele Petruzzelli, a member of Erwin Wagner’s group at the Spanish National Cancer Research Centre (CNIO), has been looking for ways to attack the disease indirectly.
read press release 

Why the Immune System Fails to Kill HIV

(Karolinska Institutet [Stockholm, Sweden]) July 18, 2014 - Some of our immune system's cells are specifically tasked with killing cells infected with the HIV virus – and researchers from Karolinska Institutet, together with international colleagues, have for the first time identified a key explanation for why these cells are unsuccessful in their task.
read article 

Queen's University Belfast in Bowel Cancer Discovery

(BBC News) July 18, 2014 - Researchers at Queen's University in Belfast have said they have made a "significant breakthrough" in the potential treatment of bowel cancer.
read article 

Saltier Intravenous Fluids Reduce Complications From Surgery

(Thomas Jefferson University) July 15, 2014 - Adequate hydration via a saline drip is essential during surgery, but recent reports suggest that getting the balance of salt and water just right could have an important impact on patient recovery.
read press release 

Lung Cancer Metastasis Trigger Found

(San Diego Union-Tribune) July 17, 2014 - A new tumor suppressor gene discovered by Salk Institute scientists may benefit an estimated 20 percent of lung cancer patients who are most likely to be helped by experimental drugs that inhibit metastasis.
read article 

GSK's Melanoma Study Stopped Early on Survival Boost

(PharmaTimes [UK]) July 17, 2014 - GlaxoSmithKline has stopped a Phase III study of its combination therapy for advanced cutaneous melanoma ahead of schedule after it showed a significant survival benefit.
read article 

Trametinib (Mekinist) and Dabrafenib (Tafinlar) Combination Demonstrated Overall Survival Benefit Compared to Vemurafenib; Phase III BRAF V600-mutant Metastatic Melanoma Study Stopped Early

(GSK) July 17, 2014 - GlaxoSmithKline plc announced today that the Independent Data Monitoring Committee (IDMC) recommended COMBI-v (MEK116513), a phase III study of its MEK inhibitor, trametinib (Mekinist™), in combination with its BRAF inhibitor, dabrafenib (Tafinlar™), compared to vemurafenib in patients with BRAF V600E or V600K mutation-positive unresectable or metastatic cutaneous melanoma be stopped early.
read corporate press release 

Helsinn Group and Chugai Pharma Marketing Enter Into Agreement for Marketing Rights of Netupitant-Palonosetron Fixed-Dose Combination (NEPA) in the UK and Ireland and for Palonosetron Monotherapy in the UK

(MarketWatch) July 17, 2014 - Under the exclusive agreement, Chugai Pharma Marketing gains rights for the marketing of palonosetron in the UK and NEPA in the UK and in Ireland from Helsinn Group, strengthening the existing alliance between the companies in therapeutic area of supportive cancer care.
read article 

Opinion: Hepatitis C Drug Worth the Price: Opposing View

(USA Today) July 16, 2014 - It will save money for our health care system in the long run.
read article 

Editorial: Why $1,000 a Pill? Our View

(USA Today) July 16, 2014 - The main reason drug makers demand such prices is because they can.
read article 

Heart Warnings For Low T Drugs? Health Canada Says ‘Yes,’ But FDA Isn’t Sure

(Wall Street Journal/Pharmalot blog) July 17, 2014 - File this under ‘a study in contrasts.’ Within 24 hours, two regulatory agencies took notably different positions on the virtues of low testosterone medications.
read article (paid subscription required) 

Don't Take Niacin For Heart Health, Doctors Warn

( July 17, 2014 - Niacin, or vitamin B3, is too dangerous and should not be used routinely by people looking to control their cholesterol levels or prevent heart disease, doctors say.
read article 

Trying Gene Therapy to Create Biological Pacemaker

(ABC/Associated Press) July 16, 2014 - No batteries required: Scientists are creating a biological pacemaker by injecting a gene into the hearts of sick pigs that changed ordinary cardiac cells into a special kind that induces a steady heartbeat.
read article 

Alzheimer Researchers See Protein as Target for Drugs

(Bloomberg) July 16, 2014 - A protein discovered less than a decade ago appears to play a role in whether symptoms of Alzheimer’s disease emerge, suggesting another avenue for exploration in efforts to find a treatment.
read article 

Foundation Medicine Receives Approvals From New York State Department of Health For FoundationOne® and FoundationOne Heme®

(MarketWatch) July 17, 2014 - Foundation Medicine, Inc. today announced that it has received final approval from the New York State Department of Health for FoundationOne® and FoundationOne Heme®.
read article